SCHEMBL22191387

SCHEMBL22191387

O=c1[nH]c2ccc(-c3ccc(NCc4cccc5ccccc45)nc3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ DYRK1A Q13627 1/20 0.46
▸ PIK3CB P42338 4/20 0.46
▸ PIK3CA P42336 3/20 0.46
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ GAA P10253 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ IDH1 O75874 2/20 0.41
▸ MAPK14 Q16539 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ ACHE P22303 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22191264 0.89 DYRK1A (0.48) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL29437806 0.89 DYRK1A (0.48) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL22191709 0.84 PIK3CB (0.46) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL29437825 0.84 PIK3CB (0.46) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL22191334 0.83 PLK4 (0.48) KMT2ALMNADYRK1AKDM4EPLK4
SCHEMBL22191663 0.82 GAA (0.46) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL22191275 0.81 GAA (0.48) MAPTMEN1KMT2ALMNADYRK1A
SCHEMBL29664534 0.79 PIK3CB (0.46) MAPTMEN1KMT2ADYRK1APIK3CB
SCHEMBL22191831 0.76 GPR55 (0.57) MAPTMEN1KMT2ADYRK1ACYP2C9
SCHEMBL21155876 0.75 DYRK1A (0.59) MAPTDYRK1APIK3CBPIK3CACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3906233-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-31 — — EP disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 — — US disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 — — US disclosed
EP-3906233-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 — — EP disclosed
CN-113508111-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2021-10-15 — — CN disclosed
WO-2020142485-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE MAP3K20, MAP3K1, PACSIN2 MAPT 1320/4885MEN1 1449/4885KMT2A 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback